Ken Griffin Milestone Pharmaceuticals Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.29 - $1.65 $20,253 - $25,905	-15,700 Reduced 98.74%	200 $0
Q2 2024 Aug 14, 2024	BUY	$1.29 - $1.83 $16,254 - $23,058	12,600 Added 381.82%	15,900 $20,000
Q1 2024 May 15, 2024	BUY	$1.4 - $2.2 $3,779 - $5,940	2,700 Added 450.0%	3,300 $5,000
Q4 2023 Feb 14, 2024	SELL	$1.67 - $3.39 $1,336 - $2,712	-800 Reduced 57.14%	600 $1,000
Q3 2023 Nov 14, 2023	BUY	$2.68 - $3.69 $3,484 - $4,797	1,300 Added 1300.0%	1,400 $4,000
Q2 2023 Aug 14, 2023	SELL	$2.85 - $4.4 $15,960 - $24,640	-5,600 Reduced 98.25%	100 $0
Q1 2023 May 15, 2023	BUY	$3.14 - $4.2 $17,898 - $23,940	5,700 New	5,700 $22,000
Q3 2022 Nov 14, 2022	BUY	$5.86 - $9.43 $1.82 Million - $2.94 Million	311,400 Added 884.66%	346,600 $3.19 Million

28.6M

200

Ticker MIST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,010,900
Market Cap $51M
Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II cl...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.